Itolizumab to treat COVID-19:
#GS3#science and Technology#
- Itolizumab (rDNA origin), a monoclonal antibody that was already approved for severe chronic plaque psoriasis, has now been granted Restricted Emergency Use authorization by the Drugs Controller General of India (DCGI) based on clinical trials data.
- M/s Biocon has been manufacturing and marketing this drug for the treatment of patients with moderate to severe chronic plaque psoriasis since 2013 under brand name Alzumab. This indigenous drug has now been repurposed for COVID-19.